RAY DEBANJAN 4
4 · CytomX Therapeutics, Inc. · Filed Jul 3, 2018
Insider Transaction Report
Form 4
RAY DEBANJAN
Chief Financial Officer
Transactions
- Sale
Common Stock
2018-07-02$22.56/sh−3,000$67,680→ 5,928 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-07-02−3,000→ 2,710 totalExercise: $1.26Exp: 2023-12-10→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2018-07-02$1.26/sh+3,000$3,780→ 8,928 total
Footnotes (2)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]100% of the shares subject to the option are fully vested and exercisable.